Breckenridge announced that the FDA has approved its Abbreviated New Drug Application (ANDA) for Rizatriptan Benzoate Orally-Disintegrating Tablets, the generic version of Merck’s Maxalt-MLT.

RELATED: Pain Management Resource Center

Maxalt-MLT is a selective 5-HT1B/1D receptor agonist indicated for the acute treatment of migraine. Rizatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Maxalt-MLT presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.

Rizatriptan Benzoate Orally Disintegrating Tablets are available in 5mg and 10mg strengths.

For more information call (561) 443 – 3314 or visit